Millennium Management Acquires Additional Larimar Therapeutics Shares for $2.91 Each

Millennium Management LLC acquired 2,890,590 shares of Larimar Therapeutics Inc at $2.91 per share, increasing its total holdings to 3,563,602 shares. The acquisition represents 0.01% of Millennium Management's total holdings and highlights the firm's interest in the biotechnology sector, despite Larimar Therapeutics' current financial challenges.

On June 12, 2025, Millennium Management LLC, a prominent hedge fund, made a strategic move by acquiring an additional 2,890,590 shares of Larimar Therapeutics Inc (LRMR, Financial), increasing its total holdings to 3,563,602 shares. This transaction, executed at a price of $2.91 per share, represents a minor portion of Millennium Management's extensive portfolio, accounting for 0.01% of its total holdings [1].

Millennium Management LLC, founded in 1989 by Israel Englander and Ronald Shear, has grown into a formidable hedge fund with over $30 billion in assets under management. The firm specializes in hedge fund management, employing strategies such as statistical arbitrage, fundamental long-short pairing, and merger arbitrage. With a global investment scope, Millennium Management focuses on liquid asset classes and aims to achieve absolute returns while prioritizing capital preservation [1].

Larimar Therapeutics Inc is a clinical-stage biotechnology company based in the USA, specializing in developing treatments for rare diseases using its novel cell-penetrating peptide (CPP) technology platform. The company's lead product candidate, CTI-1601, is designed to treat Friedreich's ataxia, a rare genetic disorder. Despite facing significant financial challenges since its IPO in 2020, the company's market capitalization stands at $172.236 million, with a current stock price of $2.69 and a year-to-date price change of -32.92% [1].

The acquisition of additional shares in Larimar Therapeutics by Millennium Management underscores the firm's interest in the biotechnology sector, despite the company's current financial challenges. This strategic move represents a small portion of Millennium Management's portfolio but highlights the potential for growth in the development of treatments for rare diseases [1].

For value investors, Millennium Management's strategic addition of shares in Larimar Therapeutics offers insight into the potential opportunities within the biotechnology sector. While the company's current financial performance is challenging, the focus on developing treatments for rare diseases presents a unique opportunity for long-term growth. Investors should carefully evaluate the risks and opportunities associated with Larimar Therapeutics, considering the firm's innovative technology and the broader market dynamics [1].

References:
[1] https://www.gurufocus.com/news/2932864/millennium-management-llc-acquires-additional-shares-in-larimar-therapeutics-inc
[2] https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results